Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 186


Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium.

Ríos R, Lupiañez CB, Campa D, Martino A, Martínez-López J, Martínez-Bueno M, Varkonyi J, García-Sanz R, Jamroziak K, Dumontet C, Cayuela AJ, Wętek M, Landi S, Rossi AM, Lesueur F, Reis RM, Moreno V, Marques H, Jurczyszyn A, Andersen V, Vogel U, Buda G, Orciuolo E, Jacobsen SE, Petrini M, Vangsted AJ, Gemignani F, Canzian F, Jurado M, Sainz J.

Endocr Relat Cancer. 2015 Aug;22(4):545-59. doi: 10.1530/ERC-15-0029. Epub 2015 Jun 22.


Expression status of candidate genes in mesothelioma tissues and cell lines.

Melaiu O, Melissari E, Mutti L, Bracci E, De Santi C, Iofrida C, Di Russo M, Cristaudo A, Bonotti A, Cipollini M, Garritano SI, Foddis R, Lucchi M, Pellegrini S, Gemignani F, Landi S.

Mutat Res. 2015 Jan;771:6-12. doi: 10.1016/j.mrfmmm.2014.11.002. Epub 2014 Nov 13.


Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk.

Figlioli G, Chen B, Elisei R, Romei C, Campo C, Cipollini M, Cristaudo A, Bambi F, Paolicchi E, Hoffmann P, Herms S, Kalemba M, Kula D, Pastor S, Marcos R, Velázquez A, Jarząb B, Landi S, Hemminki K, Gemignani F, Försti A.

Sci Rep. 2015 Mar 10;5:8922. doi: 10.1038/srep08922.


A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people.

Garritano S, De Santi C, Silvestri R, Melaiu O, Cipollini M, Barone E, Lucchi M, Barale R, Mutti L, Gemignani F, Bonotti A, Foddis R, Cristaudo A, Landi S.

J Thorac Oncol. 2014 Nov;9(11):1662-8. doi: 10.1097/JTO.0000000000000322.


Fibromyalgia syndrome and small-fiber neuropathy.

Gemignani F.

Ann Neurol. 2014 Dec;76(6):916. doi: 10.1002/ana.24269. Epub 2014 Nov 17. No abstract available.


Fibromyalgia syndrome and small-fiber neuropathy: comment on the article by Caro and Winter.

Gemignani F.

Arthritis Rheumatol. 2014 Dec;66(12):3526-7. doi: 10.1002/art.38812. No abstract available.


MicroRNA binding site polymorphisms as biomarkers in cancer management and research.

Cipollini M, Landi S, Gemignani F.

Pharmgenomics Pers Med. 2014 Jul 23;7:173-91. doi: 10.2147/PGPM.S61693. eCollection 2014. Review.


Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.

Mannil M, Solari A, Leha A, Pelayo-Negro AL, Berciano J, Schlotter-Weigel B, Walter MC, Rautenstrauss B, Schnizer TJ, Schenone A, Seeman P, Kadian C, Schreiber O, Angarita NG, Fabrizi GM, Gemignani F, Padua L, Santoro L, Quattrone A, Vita G, Calabrese D; CMT-TRIAAL/CMT-TRAUK Group, Young P, Laurà M, Haberlová J, Mazanec R, Paulus W, Beissbarth T, Shy ME, Reilly MM, Pareyson D, Sereda MW.

Neuromuscul Disord. 2014 Nov;24(11):1003-17. doi: 10.1016/j.nmd.2014.06.431. Epub 2014 Jun 19.


Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length.

Campa D, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, Jurczyszyn A, Marques H, Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, García-Sanz R, Buda G, Gemignani F, Ríos R, Vangsted AJ, Dumontet C, Martínez-López J, Moreno MJ, Stępień A, Wątek M, Moreno V, Dieffenbach AK, Rossi AM, Butterbach K, Jacobsen SE, Goldschmidt H, Sainz J, Hillengass J, Orciuolo E, Dudziński M, Weinhold N, Reis RM, Canzian F.

Int J Cancer. 2015 Mar 1;136(5):E351-8. doi: 10.1002/ijc.29101. Epub 2014 Aug 6.


Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk.

Figlioli G, Köhler A, Chen B, Elisei R, Romei C, Cipollini M, Cristaudo A, Bambi F, Paolicchi E, Hoffmann P, Herms S, Kalemba M, Kula D, Pastor S, Marcos R, Velázquez A, Jarząb B, Landi S, Hemminki K, Försti A, Gemignani F.

J Clin Endocrinol Metab. 2014 Oct;99(10):E2084-92. doi: 10.1210/jc.2014-1734. Epub 2014 Jul 16.


Is overwork weakness relevant in Charcot-Marie-Tooth disease?

Piscosquito G, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, Vita G, Quattrone A, Padua L, Gemignani F, Visioli F, Laurà M, Calabrese D, Hughes RA, Radice D, Solari A, Pareyson D; CMT-TRIAAL & CMT-TRAUK Group.

J Neurol Neurosurg Psychiatry. 2014 Dec;85(12):1354-8. doi: 10.1136/jnnp-2014-307598. Epub 2014 Mar 21.


Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies.

Xu L, Port M, Landi S, Gemignani F, Cipollini M, Elisei R, Goudeva L, Müller JA, Nerlich K, Pellegrini G, Reiners C, Romei C, Schwab R, Abend M, Sturgis EM.

Thyroid. 2014 Jun;24(6):966-74. doi: 10.1089/thy.2013.0566. Epub 2014 May 5.


Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era.

Martino A, Campa D, Jurczyszyn A, Martínez-López J, Moreno MJ, Varkonyi J, Dumontet C, García-Sanz R, Gemignani F, Jamroziak K, Stępieł A, Jacobsen SE, Andersen V, Jurado M, Landi S, Rossi AM, Lesueur F, Marques H, Dudziński M, Wątek M, Moreno V, Orciuolo E, Petrini M, Reis RM, Ríos R, Sainz J, Vogel U, Buda G, Vangsted AJ, Canzian F.

Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):670-4. doi: 10.1158/1055-9965.EPI-13-1115. Epub 2014 Feb 12.


MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.

PLoS One. 2014 Jan 21;9(1):e85935. doi: 10.1371/journal.pone.0085935. eCollection 2014.


Variation within 3'-UTRs of base excision repair genes and response to therapy in colorectal cancer patients: A potential modulation of microRNAs binding.

Pardini B, Rosa F, Barone E, Di Gaetano C, Slyskova J, Novotny J, Levy M, Garritano S, Vodickova L, Buchler T, Gemignani F, Landi S, Vodicka P, Naccarati A.

Clin Cancer Res. 2013 Nov 1;19(21):6044-56. doi: 10.1158/1078-0432.CCR-13-0314. Epub 2013 Sep 13.


'Hyperalgesia and functional sensory loss in restless legs syndrome' by Stiasny-Kolster et al.

Gemignani F.

Pain. 2014 Jan;155(1):198-200. doi: 10.1016/j.pain.2013.09.006. Epub 2013 Sep 8. No abstract available.


Risk of differentiated thyroid carcinoma and polymorphisms within the susceptibility cancer region 8q24.

Cipollini M, Figlioli G, Garritano S, Bramante S, Maiorano L, Gnudi F, Cecchini A, De Paola F, Damicis L, Frixa T, Landi D, Cancemi L, De Santi C, Melaiu O, Foddis R, Cristaudo A, Bonotti A, Romei C, Elisei R, Pellegrini G, Barale R, Gemignani F, Landi S.

Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2121-5. doi: 10.1158/1055-9965.EPI-13-0790. Epub 2013 Sep 5.


Genome-wide association study on differentiated thyroid cancer.

Köhler A, Chen B, Gemignani F, Elisei R, Romei C, Figlioli G, Cipollini M, Cristaudo A, Bambi F, Hoffmann P, Herms S, Kalemba M, Kula D, Harris S, Broderick P, Houlston R, Pastor S, Marcos R, Velázquez A, Jarzab B, Hemminki K, Landi S, Försti A.

J Clin Endocrinol Metab. 2013 Oct;98(10):E1674-81. doi: 10.1210/jc.2013-1941. Epub 2013 Jul 26.


More targets, more pathways and more clues for mutant p53.

Garritano S, Inga A, Gemignani F, Landi S.

Oncogenesis. 2013 Jul 1;2:e54. doi: 10.1038/oncsis.2013.15.


TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations.

Cipollini M, Pastor S, Gemignani F, Castell J, Garritano S, Bonotti A, Biarnés J, Figlioli G, Romei C, Marcos R, Cristaudo A, Elisei R, Landi S, Velázquez A.

Int J Cancer. 2013 Dec 15;133(12):2843-51. doi: 10.1002/ijc.28317. Epub 2013 Jul 13.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk